Ultragenyx Pharmaceutical develops and commercializes treatments for rare and ultra-rare genetic diseases, including metabolic, bone, and gene-therapy programs.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Louis Bacon / Moore | 55 | Trimmed -45% | 270,000 | $8,121,600 | 0.1% |
| Steve Cohen / Point72 | — | Trimmed -44% | 9,729 | $292,656 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-02-18 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.